

10. (Amended) The method of claim 7, wherein said trefoil protein is spasmolytic peptide (SP).

11. (Amended) The method of claim 7, wherein said trefoil protein is pS2.

### REMARKS

#### The Invention

This invention provides methods for treating a disorder or lesion of the eye by administering an intestinal trefoil peptide.

#### Support for Amendments

Support for the amendments to claims 1 and 7 is found in the specification at page 13, lines 21-23. No new matter is introduced by these amendments.

A “marked up” version of the claims showing the changes made and an appendix of the claims as pending are attached.

#### The Office Action

Claims 1-12 are pending in this application. Claims 1-12 stand rejected under 35 U.S.C. § 112, first paragraph, for a lack of enablement, and under 35 U.S.C. § 112, second paragraph, for indefiniteness. Claims 1, 2, 6, 7, and 12 are further rejected under 35 U.S.C. § 102(b) as being anticipated by U.S. Patent No. 5,703,047.

#### Rejections Under 35 U.S.C. § 112, first paragraph

Claims 1-12 are rejected under 35 U.S.C. § 112, first paragraph, for lack of enablement. Specifically, the Examiner states that, while enabling for a method of enhancing corneal epithelial wound healing using ITF, the specification does not enable